← Back to Search

Opioid Analgesic

ITM + Bupivacaine QLB for Postoperative Pain (qlcsection Trial)

Phase 3
Recruiting
Research Sponsored by Nicholas Schott
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Gestational age of at least 37 weeks
Intention to breastfeed infant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 min, 30 min, 45 min, 1 hour, and 4 hours post-operatively
Awards & highlights

qlcsection Trial Summary

This trial compared two methods of pain control after cesarean surgery.

qlcsection Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

qlcsection Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 min, 30 min, 45 min, 1 hour, and 4 hours post-operatively
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 min, 30 min, 45 min, 1 hour, and 4 hours post-operatively for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
VAS pain score with movement
Secondary outcome measures
36-Item Short Form Survey (SF-36)
Anesthetic toxicity
Blood pressure
+14 more

qlcsection Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ITM + Bupivacaine QLBExperimental Treatment1 Intervention
Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.
Group II: ITM + Sham QLBPlacebo Group1 Intervention
Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.

Find a Location

Who is running the clinical trial?

Nicholas SchottLead Sponsor
Amy MonroeStudy DirectorUniversity of Pittsburgh

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the common medical conditions that ITM + Bupivacaine QLB is used to treat?

"ITM + Bupivacaine QLB is an effective medical intervention for permphigus, acute nonspecific tenosynovitis, and general anesthesia."

Answered by AI

Does the age limit for this test extend past 75 years old?

"This particular clinical trial is only seeking patients that are 18 to 45 years of age. In contrast, there are 515 trials for seniors and 90 for minors."

Answered by AI

Are there any other cases in which ITM + Bupivacaine QLB have been studied?

"There are currently 123 on-going clinical trials evaluating ITM + Bupivacaine QLB, with 20 of them being in Phase 3. The majority of these ITM + Bupivacaine QLB trials are based in Philadelphia, but there are a total of 169 locations running these clinical trials."

Answered by AI

Might this medication be appropriate for me?

"This study is looking for around 60 participants who are postoperative and aged 18-45. To be eligible, candidates must also be experiencing pain."

Answered by AI

How many individuals are being subjected to this treatment?

"Yes, you can find this information on clinicaltrials.gov. The study was first posted on September 5th, 2017 and is currently looking for 60 patients from 1 site."

Answered by AI

Are there any remaining openings for people who want to participate in this research project?

"That is correct. The clinicaltrials.gov website has information indicating that this study is still recruiting patients. The trial was first posted on September 5th, 2017 and was updated on June 2nd, 2022. Currently, the study is looking for 60 patients at 1 location."

Answered by AI

Are there any known dangers to ITM + Bupivacaine QLB?

"ITM + Bupivacaine QLB has received a safety score of 3 from our team at Power. This is because ITM + Bupivacaine QLB is a Phase 3 trial, meaning that while there is some data supporting efficacy, there are multiple rounds of data supporting safety."

Answered by AI
~8 spots leftby Mar 2025